First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis

February 23, 2017 updated by: Novo Nordisk A/S
This trial is conducted in Europe. The aim of this trial is to describe the safety and tolerability of single intravenous (i.v.) and subcutaneous (s.c.) doses of NNC0215-0384 in subjects with active rheumatoid arthritis (RA) on background methotrexate (MTX) treatment.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

36

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Berlin, Germany, 10117
        • Novo Nordisk Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Active RA, characterised by a DAS28 (CRP)(Disease Activity Score based on 28 joints and CRP) above 3.2 and a minimum of two swollen joints based on a 68/66 joint count at screening
  • Concomitant treatment with MTX (7.5 - 25 mg/week both inclusive) for at least 16 weeks, with a stable dose for at least 6 weeks prior to dosing

Exclusion Criteria:

  • Subjects with chronic inflammatory autoimmune disease other than RA
  • History of or current inflammatory joint disease other than RA such as gout (crystal proven), psoriatic arthritis, juvenile idiopathic arthritis, current reactive arthritis or Lyme disease
  • Any active or ongoing chronic infectious disease (e.g. chronic osteomyelitis, chronic pyelonephritis) requiring systemic anti-infectious treatment within 4 weeks prior to randomisation
  • Clinically significant cardiac or cardiovascular disease
  • Past or current malignancy
  • Latent or active tuberculosis (TB) as documented by: A positive QuantiFeron® test (test can be performed up to 2 months prior to dosing). One retest is allowed in case of inconclusive results.- A history of active TB within the last 3 years even, if treated effectively. - A history of active TB more than 3 years ago, if there is no documentation that the prior anti-TB treatment was appropriate in duration and type

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
PLACEBO_COMPARATOR: Placebo
Administered i.v.(intravenous) or s.c. (subcutaneous, under the skin).
EXPERIMENTAL: Active
I.v.(intravenous) dose-escalation. Highest dose planned for i.v. administration is 10 mg/kg
The s.c. (subcutaneous, under the skin) part will not start until at least two i.v. dose levels have been evaluated for safety and pharmacokinetics. Highest dose planned for s.c. administration is 4 mg/kg

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Incidence of adverse events (AEs)
Time Frame: Up to 10 weeks after trial product administration
Up to 10 weeks after trial product administration

Secondary Outcome Measures

Outcome Measure
Time Frame
I.v. administration: AUC, Area under the curve
Time Frame: Up to 10 weeks after drug administration
Up to 10 weeks after drug administration
I.v. administration: terminal half-life (t½)
Time Frame: Up to 10 weeks after drug administration
Up to 10 weeks after drug administration
S.c. administration: AUC, Area under the curve
Time Frame: Up to 10 weeks after drug administration
Up to 10 weeks after drug administration
S.c. administration: terminal half-life (t½)
Time Frame: Up to 10 weeks after drug administration
Up to 10 weeks after drug administration
Maximum level and duration of full C5a receptor (C5aR) occupancy by NNC0215-0384 on neutrophils
Time Frame: Up to 10 weeks after drug administration
Up to 10 weeks after drug administration
Maximum and minimum levels of relevant serum and plasma biomarkers related to NNC0215-0384 safety, efficacy or mechanism of action (MoA)
Time Frame: Up to 10 weeks after drug administration
Up to 10 weeks after drug administration

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

June 4, 2012

Primary Completion (ACTUAL)

June 17, 2013

Study Completion (ACTUAL)

June 17, 2013

Study Registration Dates

First Submitted

June 1, 2012

First Submitted That Met QC Criteria

June 1, 2012

First Posted (ESTIMATE)

June 5, 2012

Study Record Updates

Last Update Posted (ACTUAL)

February 27, 2017

Last Update Submitted That Met QC Criteria

February 23, 2017

Last Verified

February 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • NN8210-3926
  • 2011-003008-19 (EUDRACT_NUMBER)
  • U1111-1122-3474 (OTHER: WHO)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.